Gyre Therapeutics (NASDAQ:GYRE) Shares Up 5.8%

Gyre Therapeutics, Inc. (NASDAQ:GYRE)’s share price shot up 5.8% during trading on Monday . The company traded as high as $11.68 and last traded at $11.68. 2,801 shares were traded during trading, a decline of 96% from the average session volume of 75,306 shares. The stock had previously closed at $11.04.

Gyre Therapeutics Stock Performance

The stock has a 50-day moving average of $13.72 and a 200 day moving average of $17.31.

Gyre Therapeutics (NASDAQ:GYRE) last posted its earnings results on Thursday, May 9th. The company reported $0.04 EPS for the quarter. The business had revenue of $27.17 million during the quarter. As a group, analysts forecast that Gyre Therapeutics, Inc. will post -0.45 EPS for the current year.

Insider Buying and Selling at Gyre Therapeutics

In other Gyre Therapeutics news, Director Nassim Usman sold 20,000 shares of Gyre Therapeutics stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $14.13, for a total value of $282,600.00. Following the sale, the director now owns 1,636 shares in the company, valued at $23,116.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 2.92% of the company’s stock.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.